Biotech Astex Pharmaceuticals (NASDAQ: ASTX) made a huge pop today, after RBC gave the stock an upgrade to "outperform," calling it an "undiscovered gem" and raising the price target a whopping 40%. In this video, Motley Fool health-care analyst David Williamson tells investors about some potentially very exciting phase 2 data soon to be released by the company and gives us a picture of what it could mean for Astex if its trial data is as good as RBC thinks.
Is This Biotech an Undiscovered Gem?
By Dave Williamson
-
Apr 3, 2013 at 6:48PM
You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Could this company be a diamond in the rough for investors?
Stocks Mentioned

Johnson & Johnson
JNJ
$176.98
(1.75%)
$3.04

AstraZeneca PLC
AZN
$66.21
(2.59%)
$1.67

Celgene Corporation
CELG
*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.
Related Articles

Better Buy: Gingko Bioworks vs. Amyris

Have $2,000? 2 Market Crash-Ready Stocks to Buy

Stock Market Plunge: 5 Unstoppable Stocks on Sale to Buy Now and Hold Forever

2 Safe Stocks to Buy in a Bear Market

Tech Stock Sell-Off Got You Scared? Here's a Better Buy.
Our Most Popular Articles
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.